Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Increase in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 140,400 shares, an increase of 134.4% from the February 13th total of 59,900 shares. Based on an average daily volume of 7,730,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.4% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PSTV. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Plus Therapeutics in a report on Tuesday, November 26th. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th.

Plus Therapeutics Stock Down 9.5 %

Shares of NASDAQ PSTV traded down $0.07 during mid-day trading on Friday, reaching $0.68. 2,448,675 shares of the company were exchanged, compared to its average volume of 10,429,443. Plus Therapeutics has a 52 week low of $0.24 and a 52 week high of $2.67. The company’s 50 day moving average price is $1.13 and its 200 day moving average price is $1.26. The stock has a market capitalization of $4.00 million, a PE ratio of -0.27 and a beta of 0.73.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.